Skip to main content
Fig. 3 | Infectious Agents and Cancer

Fig. 3

From: Real-world clinical features and survival outcomes in diffuse large B-cell lymphoma patients with hepatitis B virus infection

Fig. 3

Kaplan‒Meier analysis of the OS and PFS of patients receiving different chemotherapy regimens. OS (A) and PFS (B) in HBsAg + DLBCL patients treated with CHOP/CHOP-like or R-CHOP/R-CHOP-like regimens; OS (C) and PFS (D) in HBsAg-/HBcAb + DLBCL patients treated with CHOP/CHOP-like or R-CHOP/R-CHOP-like regimens; OS (E) and PFS (F) in HBsAg-/HBcAb-DLBCL patients 28 treated with CHOP/CHOP-like or R-CHOP/R-CHOP-like regimens. OS: overall survival; PFS: progression-free survival; CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHOP: CHOP plus rituximab; HBsAg + : hepatitis B virus surface antigen positive; HBsAg-/HBcAb + : hepatitis B virus surface antigen negative/core antibody positive; HBsAg-/HBcAb-: hepatitis B virus surface antigen negative/core antibody negative; DLBCL: diffuse large B-cell lymphoma

Back to article page

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us